FY2028 EPS Estimates for Pharvaris Boosted by HC Wainwright

Pharvaris N.V. (NASDAQ:PHVS) – Research analysts at HC Wainwright lifted their FY2028 EPS estimates for shares of Pharvaris in a note issued to investors on Tuesday, October 6th. HC Wainwright analyst P. Trucchio now anticipates that the company will earn ($0.48) per share for the year, up from their previous forecast of ($0.56). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Pharvaris’ current full-year earnings is ($3.12) per share.

A number of other research analysts also recently issued reports on PHVS. Leerink Partners boosted their price target on Pharvaris from $50.00 to $65.00 and gave the company an “outperform” rating in a report on Wednesday, September 9th. Oppenheimer reissued an “outperform” rating and set a $75.00 target price on shares of Pharvaris in a research note on Tuesday, September 8th. UBS Group set a $60.00 price target on Pharvaris in a research note on Tuesday. Rosenblatt Securities set a $60.00 price target on shares of Pharvaris in a report on Wednesday, September 9th. Finally, Citizens Jmp upped their price objective on shares of Pharvaris from $75.00 to $79.00 and gave the stock a “market outperform” rating in a report on Wednesday, September 9th. Thirteen investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $58.60.

Pharvaris Trading Up 1.8%

Pharvaris stock opened at $31.68 on Thursday. The firm has a 50-day moving average of $34.91 and a 200-day moving average of $32.29. The firm has a market cap of $2.07 billion, a P/E ratio of -10.39 and a beta of -2.46. Pharvaris has a 1-year low of $20.65 and a 1-year high of $43.25.

Pharvaris (NASDAQ:PHVS) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.06).

Institutional Investors Weigh In On Pharvaris

Several institutional investors and hedge funds have recently added to or reduced their stakes in PHVS. venBio Partners LLC purchased a new stake in Pharvaris during the 2nd quarter valued at $160,569,809. Wellington Management Group LLP grew its holdings in shares of Pharvaris by 12.9% in the second quarter. Wellington Management Group LLP now owns 2,392,934 shares of the company’s stock worth $82,748,000 after acquiring an additional 274,034 shares during the period. Commodore Capital LP grew its holdings in shares of Pharvaris by 1.6% in the first quarter. Commodore Capital LP now owns 1,918,970 shares of the company’s stock worth $54,211,000 after acquiring an additional 29,525 shares during the period. 5AM Venture Management LLC purchased a new stake in Pharvaris during the second quarter valued at $27,581,008. Finally, Seven Fleet Capital Management LP increased its position in Pharvaris by 144.6% during the second quarter. Seven Fleet Capital Management LP now owns 774,501 shares of the company’s stock valued at $26,782,000 after acquiring an additional 457,804 shares during the last quarter.

Insider Buying and Selling

In related news, insider Wim Souverijns sold 20,000 shares of the business’s stock in a transaction dated Monday, September 14th. The shares were sold at an average price of $39.31, for a total transaction of $786,200.00. Following the sale, the insider owned 45,111 shares of the company’s stock, valued at $1,773,313.41. The trade was a 30.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, President Peng Lu sold 100,000 shares of the company’s stock in a transaction that occurred on Thursday, September 17th. The stock was sold at an average price of $35.00, for a total value of $3,500,000.00. Following the completion of the sale, the president owned 64,953 shares in the company, valued at $2,273,355. The trade was a 60.62% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 513,102 shares of company stock worth $18,643,666 over the last quarter. Company insiders own 11.84% of the company’s stock.

About Pharvaris

Pharvaris N.V. (NASDAQ:PHVS) is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE) and other diseases associated with bradykinin-mediated swelling. HAE is a rare genetic disorder that can cause recurring, potentially life-threatening attacks affecting areas such as the skin, gastrointestinal tract and airways.

The company’s lead program is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist formerly known as PHA121.